Exact Mass: 628.3611

Exact Mass Matches: 628.3611

Found 28 metabolites which its exact mass value is equals to given mass value 628.3611, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Lopinavir

N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide

C37H48N4O5 (628.3625)


Lopinavir is only found in individuals that have used or taken this drug. It is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.Lopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles. D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors CONFIDENCE standard compound; INTERNAL_ID 2288 Same as: D01425 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

LysoPI(20:0/0:0)

[(2R)-2-hydroxy-3-(icosanoyloxy)propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C29H57O12P (628.3587)


LysoPI(20:0/0:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(20:0/0:0), in particular, consists of one chain of arachidic acid at the C-1 position.

   

onchitriol II D|Onchitriol IID

onchitriol II D|Onchitriol IID

C36H52O9 (628.3611)


   

milbemycins VM48641

milbemycins VM48641

C36H52O9 (628.3611)


   

11-oxoasiatic acid triacetate|2alpha,3beta,23-triacetoxy-11-oxo-urs-12-en-28-oic acid|2alpha,3beta,23-Triacetoxy-11-oxo-urs-12-en-28-saeure|2alpha,3beta,23-triacetoxyurs-11-oxo-12-ene-28-oic acid

11-oxoasiatic acid triacetate|2alpha,3beta,23-triacetoxy-11-oxo-urs-12-en-28-oic acid|2alpha,3beta,23-Triacetoxy-11-oxo-urs-12-en-28-saeure|2alpha,3beta,23-triacetoxyurs-11-oxo-12-ene-28-oic acid

C36H52O9 (628.3611)


   

sapinsignoid A

sapinsignoid A

C36H52O9 (628.3611)


   

onchitriol I A|Onchitriol IA

onchitriol I A|Onchitriol IA

C36H52O9 (628.3611)


   

Lopinavir

Lopinavir (ABT-378)

C37H48N4O5 (628.3625)


D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Same as: D01425 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

RLLNN

Arg-Leu-Leu-Asn-Asn

C26H48N10O8 (628.3656)


   

PI(20:0/0:0)

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587)


   

LPI 20:0

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587)


   

LysoPI(20:0/0:0)

LysoPI(20:0/0:0)

C29H57O12P (628.3587)


   
   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

C37H48N4O5 (628.3625)


   

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

C37H48N4O5 (628.3625)


   

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] icosanoate

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] icosanoate

C29H57O12P (628.3587)


   

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

C29H57O12P (628.3587)


   

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587)


   
   
   
   

(2r,3r,4s,5s,6e,8r)-8-{6-[(2s,3s)-3-(acetyloxy)pentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-4,6-dimethylnon-6-en-3-yl acetate

(2r,3r,4s,5s,6e,8r)-8-{6-[(2s,3s)-3-(acetyloxy)pentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-4,6-dimethylnon-6-en-3-yl acetate

C36H52O9 (628.3611)


   

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C36H52O9 (628.3611)


   

6-(but-2-en-2-yl)-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

6-(but-2-en-2-yl)-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C36H52O9 (628.3611)


   

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6r)-6-hydroxytetradeca-2,4-dienoate

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6r)-6-hydroxytetradeca-2,4-dienoate

C36H52O9 (628.3611)


   

(3s,6s,9s,12s,20as)-12-benzyl-1,4,7,10,13-pentahydroxy-6-[(1r)-1-hydroxyethyl]-3,9-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

(3s,6s,9s,12s,20as)-12-benzyl-1,4,7,10,13-pentahydroxy-6-[(1r)-1-hydroxyethyl]-3,9-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C32H48N6O7 (628.3584)


   

(2r,3r,4r,5r,6e,8s)-5-(acetyloxy)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-8-{6-[(2s,3s)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethylnon-6-en-3-yl acetate

(2r,3r,4r,5r,6e,8s)-5-(acetyloxy)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-8-{6-[(2s,3s)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethylnon-6-en-3-yl acetate

C36H52O9 (628.3611)


   

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6s)-6-hydroxytetradeca-2,4-dienoate

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6s)-6-hydroxytetradeca-2,4-dienoate

C36H52O9 (628.3611)